Grufity logo
Grufity logo
ANEB

ANEB - Anebulo Pharmaceuticals, Inc. Stock Price, Fair Value and News

$0.48+0.01 (+2.13%)
Market Closed as of 15 Jun 2026, 04:00 pm ET

39/100

ANEB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

39/100

ANEB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ANEB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANEB Price Action

Last 7 days

23.7%

Last 30 days

-9.6%

Last 90 days

-14.5%

Trailing 12 Months

-63.0%

ANEB RSI Chart

ANEB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANEB Valuation

Market Cap

19.7M

Price/Earnings (Trailing)

-2.47

Price/Sales (Trailing)

38.93

EV/EBITDA

-2.09

Price/Free Cashflow

-3.38

ANEB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ANEB Fundamentals

ANEB Revenue

Rev. Growth (Yr)

210.95%

Rev. Growth (Qtr)

51.33%

ANEB Earnings

Earnings (TTM)

-8.0M

Earnings Growth (Yr)

18.82%

Earnings Growth (Qtr)

7.36%

ANEB Profitability

EBT Margin

-991.06%

Return on Equity

-100.53%

Return on Assets

-84.68%

Free Cashflow Yield

-29.61%

ANEB Investor Care

Shares Dilution (1Y)

54.02%

Diluted EPS (TTM)

-0.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025----
2024222.8K193.8K393.8K496.0K
202371.1K92.4K-163.5K
2022-7.3K28.6K49.9K
2021-1.0K--
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Anebulo Pharmaceuticals, Inc.

ANEB
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.
 CEO
 WEBSITEanebulo.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES4

Anebulo Pharmaceuticals, Inc. Frequently Asked Questions

ANEB is the stock ticker symbol of Anebulo Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Anebulo Pharmaceuticals, Inc. is 19.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, ANEB's PE ratio (Price to Earnings) is -2.47 and Price to Sales (PS) ratio is 38.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANEB PE ratio will change depending on the future growth rate expectations of investors.